Indian Academy of Pediatrics (IAP)

STANDARD
TREATMENT
GUIDELINES 2022

Childhood
Systemic Lupus
Erythematosus
Lead Author
Nutan Kamath
Co-Authors
Amit Rawat, Aaradhana Singh

Under the Auspices of the IAP Action Plan 2022

Remesh Kumar R
IAP President 2022
Upendra Kinjawadekar Piyush Gupta
IAP President-Elect 2022 IAP President 2021
Vineet Saxena
IAP HSG 2022–2023
© Indian Academy of Pediatrics

IAP Standard Treatment Guidelines Committee

Chairperson
Remesh Kumar R
IAP Coordinator
Vineet Saxena
National Coordinators
SS Kamath, Vinod H Ratageri
Member Secretaries
Krishna Mohan R, Vishnu Mohan PT
Members
Santanu Deb, Surender Singh Bisht, Prashant Kariya,
Narmada Ashok, Pawan Kalyan
 Childhood Systemic
131
Lupus Erythematosus
Definition

Childhood Systemic Lupus Erythematosus (cSLE) is a chronic heterogeneous autoimmune

disease associated with considerable morbidity and significant mortality. It is characterized by
multisystem sequential or simultaneous organ involvement (predominant musculoskeletal,
cutaneous, renal, hematologic and neuropsychiatric manifestations) and presence of anti­
nuclear and other antibodies.

Classification Criteria for SLE

Clinical Manifestations and

Source: Adapted from European League Against Rheumatism/American College of Rheumatology

classification criteria for systemic lupus erythematosus; 2019.
 Childhood Systemic Lupus Erythematosus
Severity of Illness

Mild SLE: No renal or other life-threatening organ system involvement

Moderate SLE: Clinically significant but not life-threatening involvement

of kidneys or other vital organs/systems

Severe SLE: Major organ threatening disease

Laboratory investigations form integral part of diagnosis and management of patients with SLE.

General laboratory investigations

Erythrocyte Increase in ESR is in proportion to disease activity. May be falsely elevated
sedimentation rate (ESR) in hypergammaglobulinemia
C-reactive protein ;; Usually normal even with active disease
;; Increased in patients with concomitant infection, serositis or arthritis
Ferritin Increased, albeit not as much as in macrophage activation syndrome
Specific mmunological investigations
Method of detection Comments

Investigations
Antinuclear antibodies Indirect immunofluorescence Present in more than 90% of
(ANA) on HEp2 cells remains the gold children with lupus. Patterns of
standard for detection staining may reflect antigenic
specificity of the antibody
Anti-double stranded Enzyme immunoassay or ;; High specificity for SLE
antibodies (anti-dsDNA) immunofluorescence ;; Marker for active disease
especially lupus nephritis
Complement estimation Nephelometry or enzyme Complement C3 and C4 are
immunoassay commonly measured. Low levels
detected in active disease
Extractable nuclear Can be detected by Provide useful information on
antigens immunoblotting or by antigenic specificity of ANA
counterimmunoelectrophoresis
Antiphospholipid (aPL) ;; ELISA for anticardiolipin and Positive in significant proportion
antibodies anti-β2-glycoprotein I antibodies of pediatric SLE patients.
;; Lupus anticoagulant assay by Anticoagulants (heparin and oral
activated partial thromboplastin anticoagulants) may interfere with
time (aPTT) and dilute Russell’s detection of lupus anticoagulant
viper venom time (dRVVT)
4
 Childhood Systemic Lupus Erythematosus

Treatment
Childhood systemic lupus erythematosus ranges in severity from mild disease with arthritis
and rash to devastating nephritis with renal failure or profound neurological disturbances.
Approach to therapy is individualized for each patient and based on the clinical features.
Nevertheless, treatment is unified based on a few guiding principles.

1. Treatment by multidisciplinary team with the paediatric rheumatologist as the Lead

Ten Principles of

2. Assess organ involvement

3. Assess disease activity and damage index
Treatment

4. Direct therapy to specific disease manifestations that are active

5. Achieve remission with adequate immunosuppression
6. Therapy for the shortest time period and at lowest possible doses
7. Maintain remission with minimal toxicity of drugs
8. Prompt recognition and aggressive treatment of ‘flares’ and infection
9. Counsel and educate parents and child
10. Transition to adult care in late adolescence

Avoid sun exposure, Aggressive treatment of

Adequate nutrition use water-based sunscreen infections
with SPF >30

General Treatment
Immunize for age with Recognise “Flare of disease
non-live vaccines in cSLE Calcium and vitamin D activity” (development of
(influenza, hepatitis supplementation if on steroids new symptoms and signs
A and B, human folic acid supplementation if which require a change in
papilloma, meningococcal, on methotrexate therapy)
pneumococcal, COVID-19)

Maintain attendance and

Maintain normal blood participation in all school Ensure good mental health
pressure activities to maximum
extent possible

5
 Childhood Systemic Lupus Erythematosus
Organ Specific Treatment

Based on severity of involvement

Assess Disease
Damage Index
Activity and
Assessment of disease activity and damage is best done by pediatric rheumatologist
using SLE Disease Activity Index (SLEDAI)/British Isles Lupus Assessment Group
(BILAG) index and paediatric version of American College of Rheumatology/Systemic
Lupus International Collaborating Clinics (ACR/SLICC) damage score index.
Counseling and Education

;; About chronic nature of illness with flares and remissions

;; Regular follow-up
;; Monitoring for side effects of drugs
;; Need for prolonged therapy
;; Access to patient information material
;; Need for shared care with multidisciplinary team
;; Career choices
;; Transition to medical care in late adolescence
;; Coping strategies for parents and child

6
 Childhood Systemic Lupus Erythematosus

Name Dosage Indications Important side Monitoring

effects
Prednisolone Initiation of therapy (4–6 Mainstay of Obesity, Regular blood
weeks): 0.5–2 mg/kg/ treatment to induce glaucoma, pressure
day (max 60 mg/day) and maintain cataract, and random
in at least two divided remission hypertension, blood sugar
doses based on type growth monitoring,
and severity of organ suppression, calcium and
involved. diabetes, vitamin D
Tapering dose: Reduce osteoporosis, supplement,

Drugs used in Management of SLE

by 2.5–5 mg/week till a avascular bone density
daily dose of 20 mg necrosis of bone, monitoring
Further reduction by infections
1–2.5 mg every
2–4 weeks till a daily
dose of 10 mg
After a daily dose of
10 mg is reached,
reduce by 0.5–1 mg
every 2–4 weeks
Intravenous 10–30 mg/kg to a Severe cytopenias, Hypertension, Monitoring of
pulse methyl maximum of 1 g/day proliferative hyperglycemia vitals especially
prednisolone for 1–5 consecutive nephritis, major Rest of the side- blood pressure
days followed by oral CNS disease, effects similar to before starting
prednisolone as above vasculitis, “lupus prednisolone and during
crisis” infusion
Hydroxy­ 4–6 mg/kg/day at Cutaneous disease Nausea, Eye check at
chloroquine bedtime (maximum and adjunct pruritis, rarely starting drug
dose 400 mg/day) to steroids for maculopathy and biannually
systemic disease for visual acuity,
color vision
testing, visual
field testing, and
retinoscopy
Metho­trexate 10–15 mg/m2 ;; Arthritis GI intolerance, AST/ALT, serum
subcutaneously weekly ;; Resistant skin mouth ulcers, albumin, CBC
once disease alopecia, at baseline
bone marrow and then at
suppression, 8–12 weeks
hepatotoxicity intervals
Contd...

7
 Childhood Systemic Lupus Erythematosus

Contd...
Name Dosage Indications Important side Monitoring
effects
Nonsteroidal GI intolerance/ bleed, AST/ALT, serum
anti- renal impairment, creatinine at
inflammatory hypersensitivity baseline and 6
drugs (NSAIDs) month intervals
Naproxen 15–20 mg/kg/day Myalgia, arthralgia, Pseudoporphyria-
in two divided arthritis pruritis, urticarial,
doses (maximum morbiliform rash,
dose 1 g) erythema multiforme
Drugs used in Management of SLE

Ibuprofen 30–40 mg/kg/day Positive aPL

in three divided antibodies
doses (maximum
dose 2.4 g)
Aspirin 3–5 mg/kg/day
Cyclophos­ 1–2 mg/kg/day Severe cytopenias, Nausea, vomiting, Ensure adequate
phamide (PO) or 500–1000 proliferative cytopenias, fluid intake
mg/m2/month (IV) nephritis, major infections, CBC on day 7
in severe disease CNS disease, hemorrhagic cystitis and 14 if on
vasculitis pulse therapy
Azathioprine 0.5–2.5 mg/kg/day Mild SLE Cytopenias, CBC monthly
(PO) unresponsive to pancreatitis and after dose
(Maximum glucocorticoids and Opportunistic increments,
150 mg/day) HCQS or develop infections hepatic
unacceptable drug enzymes, BUN,
toxicity creatinine
amylase and
lipase at onset
of treatment
and every
3 months
Mycophenolate 1200–1800 mg/ Induction and ;; GI intolerance CBC every
Mofetil m2/day twice maintenance of ;; Pancytopenia 8–12 weeks
daily (PO) severe cytopenias, ;; Opportunistic
(Maximum vasculitis, infections
3000 mg/day) proliferative and
membranous
nephritis,
steroid sparing in
moderate to severe
illness
Contd...

8
 Childhood Systemic Lupus Erythematosus

Contd...
Name Dosage Indications Important side Monitoring
effects
Cyclosporine 2.5–5 mg/kg/day Membranous nephrotoxic Blood urea
A nephropathy nitrogen,

Drugs used in Management of SLE

creatinine, urine
analysis, hepatic
enzymes, CBC at
start of therapy
and monthly
IV Immuno­ Up to 2 g/kg Severe Anaphylaxis, Monitor blood
globulin thrombocytopenia, Aseptic pressure and
catastrophic meningitis pulse rate every
anti-phospholipid (Headache, 15 minutes for
syndrome vomiting first hour, every
18–36 hours 30 minutes for
after the second hour,
infusion) every hour
thereafter
Rituximab 375 mg/m2/week Severe and Infection Monitor CBC at
intravenously (four doses refractory disease Hypogamma­ start of therapy
at interval of 7 days) OR globulinemia
750 mg/m2 ( two doses at Infusion
interval of 14 days) reaction
Belimumab 10 mg/kg every Clinically active Infection Monitor CBC at
(approved 4 weeks disease without start of therapy
for children severe nephritis or and monthly
> 5 years) neuropsychiatric
lupus
(CBC: complete blood count; ALT: alanine transaminase; AST: aspartate aminotransferase)
Complications

9
 Childhood Systemic Lupus Erythematosus
Role of General Pediatrician (GP)

Early recognition and

referral to specialist Liaison with rheumatologist Treat intercurrent infections
(URGENT referral if major for shared care aggressively
organ involvement)

Maintain immunization
Never stop
schedule. Administer
immunosuppression
non-live vaccines. Discuss Counsel parents and child
without discussion with the
about live vaccines with
rheumatologist
the rheumatologist

Prognosis
Early diagnosis and appropriate therapy ensures good prognosis. Intercurrent infections, flares,
renal and cardiovascular disease, neurologic manifestations and poor adherence to treatment
affects outcome. Morbidity of the disease and adverse effects of the medications must be
minimized to achieve satisfactory long-term outcome.

Misnomer as the neonate is

Etiology: Transplacental Autoantibodies are
not affected by SLE and in
Neonatal Lupus

transfer of maternal usually specific for Ro/SSA

addition, the mother is often
autoantibodies with antigen, La/SSB antigen or
asymptomatic or suffering
narrow range of antigenic rarely U1RNP
from an autoimmune disease
specificity
other than lupus

Mere transfer of maternal

Congenital heart block is
autoantibodies is not sufficient
a dreaded complication of
for the development of
neonatal lupus
neonatal lupus

10
 Childhood Systemic Lupus Erythematosus

Medications associated with drug-induced lupus

;; Procainamide ;; Phenytoin
;; Hydralazine ;; Carbamazepine

Drug-induced Lupus
;; Minocycline ;; Valproate
;; Isoniazid, Rifampicin ;; Penicillamine
;; Amiodarone

Clinical characteristics Management

;; Males and females equally ;; Withdraw the

affected offending medication
;; Hepatitis more common ;; Hydroxychloroquine,
;; Anti-dsDNA and NSAIDs and steroids
hypocomplementemia less may be required for
common short duration
;; Significant renal/neurologic
disease less likely
;; Anti-histone antibodies
(>95 %)

Infections
Lupus Mimics

Viral Epstein-Barr virus, Cytomegalovirus, Parvovirus B19, Human Herpes Virus 6

Bacterial Brucellosis, Leptospirosis, Q fever, Mycoplasma
Spirochetal Lyme disease
Protozoal Toxoplasmosis
Malignancy Leukemia, Lymphoma
Other autoimmune Mixed connective tissue disease, systemic vasculitis, antiphospholipid
diseases syndrome, juvenile dermatomyositis

11
 Childhood Systemic Lupus Erythematosus
Summary

Diagnosis and management of cSLE is a challenge due to its myriad clinical presentations.
Shared care pathways between specialists from different disciplines and different levels of care
(primary, secondary, and tertiary) are of paramount importance in management of cSLE.

;; Aringer M, Costenbader K, Daikh D, et al. 2019 European League against Rheumatism/American

College of Rheumatology classification criteria for systemic lupus erythematosus. Arthritis

Further Reading
Rheumatol. 2019;71(9):1400-12.
;; Gergianaki I, Bertsias G. Systemic lupus erythematosus in primary care: an update and practical
messages for the general practitioner. Front Med (Lausanne). 2018;5:161.
;; Groot N, de Graeff N, Marks SD, Brogan P, Avcin T, Bader-Meunier B, et al. European evidence-based
recommendations for the diagnosis and treatment of childhood-onset lupus nephritis: the SHARE
initiative. Ann Rheum Dis. 2017;76(12):1965-73.
;; Massias JS, Smith EMD, Al-Abadi E, et al. Clinical and laboratory characteristics in juvenile-onset
systemic lupus erythematosus across age groups. Lupus. 2020;29(5):474-81.
;; Trindade VC, Carneiro-Sampaio M, Bonfa E, Silva CA. An update on the management of childhood-
onset systemic lupus erythematosus. Paediatr Drugs. 2021;23(4):331-47.

12